We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




AI Algorithm Detects Early-Stage Metabolic-Associated Steatotic Liver Disease Using EHRs

By MedImaging International staff writers
Posted on 25 Nov 2024
Print article
Image: AI can find undiagnosed liver disease in early stages (Photo courtesy of 123RF)
Image: AI can find undiagnosed liver disease in early stages (Photo courtesy of 123RF)

Liver disease, which is treatable when detected early, often goes unnoticed until it reaches advanced stages. Metabolic-associated steatotic liver disease (MASLD), the most prevalent form of liver disease, occurs when the liver is unable to properly manage fat, and it is commonly linked to conditions like obesity, Type-2 diabetes, and high cholesterol. Early detection of MASLD is crucial because it can rapidly progress to more severe liver conditions, but many individuals in the early stages show no symptoms, making diagnosis difficult. Now, a new study has demonstrated that an artificial intelligence (AI)-powered algorithm can accurately identify early-stage MASLD by analyzing electronic health records (EHRs).

Researchers at the University of Washington (Seattle, WA, USA) employed an AI algorithm to examine imaging data within EHRs from three sites in the University of Washington Medical System to identify patients who met the criteria for MASLD. Of the 834 patients identified, only 137 had a formal MASLD diagnosis recorded. This means that 83% of patients who met the criteria for MASLD were undiagnosed, despite the data in their EHRs indicating they were at risk.

“A significant proportion of patients who meet criteria for MASLD go undiagnosed. This is concerning because delays in early diagnosis increase the likelihood of progression to advanced liver disease,” said Ariana Stuart MD, a resident at University of Washington Internal Medicine Residency Program and lead author of the study. “People should not interpret our findings as a lack of primary care training or management. Instead, our study shows how AI can complement physician workflow to address the limitations of traditional clinical practice.”

New
Ultrasound-Guided Biopsy & Visualization Tools
Endoscopic Ultrasound (EUS) Guided Devices
Portable X-ray Unit
AJEX140H
New
Pocket Fetal Doppler
CONTEC10C/CL
New
Mobile X-Ray Machine
MARS 15 / 30

Print article

Channels

MRI

view channel
Image: An AI tool has shown tremendous promise for predicting relapse of pediatric brain cancer (Photo courtesy of 123RF)

AI Tool Predicts Relapse of Pediatric Brain Cancer from Brain MRI Scans

Many pediatric gliomas are treatable with surgery alone, but relapses can be catastrophic. Predicting which patients are at risk for recurrence remains challenging, leading to frequent follow-ups with... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.